Esperion Therapeutics Inc. announced positive results Wednesday from a late-stage trial of a treatment for atherosclerotic cardiovascular disease, a condition involving a build-up of sticky cholesterol-rich plaque that can cause heart attack or stroke. Esperion said the phase 3 trial of bempedoic acid for patients with elevated low density lipoprotein cholesterol (LDL-C) met its primary endpoint of LDL-C lowering. “Patients treated with bempedoic acid also achieved a significantly greater reduction of 33 percent in high-sensitivity C-reactive protein (hsCRP), an important marker of the underlying inflammation associated with cardiovascular disease, compared to the placebo group which had an increase of two percent (p
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News